Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

691 results about "Polyamino acid" patented technology

Polyamino Acids. Polyamino acids (PAA) have properties that mimic proteins, making them ideal for both drug delivery and the delivery of nucleic acids both in vitro and in vivo. These properties include increasing solubility and stability of drug attachments, drug encapsulation, drug targeting, bypassing multidrug resistance (MDR) factors,...

Composite gel microparticles as active principle carriers

The invention relates to vectors for delivering medicinal, nutritional, plant-protection or cosmetic active principles, these delivery particles being of small, controllable and adjustable particle size, which protect the active principle, and being biocompatible, biodegradable, non-immunogenic, stable and free of solvent. The particles do not denature the active principle and allow the active principle to be released. The microparticles of the invention are of a cohesive structure made of a physicochemically stable and integral composite gel which includes an oil such as coconut oil, an aqueous phase and a linear, non-crosslinked copolyamino acid of Leu / Glu type (random or diblock). The microparticles have a controllable and adjustable size of between 0.05 and 500 mum.
Owner:FLAMEL TECHNOLOGIES

Nucleic acid formulations for gene delivery and methods of use

A nucleic acid formulation for use in gene delivery comprising a nucleic acid and an anionic polymer is disclosed. Examples of the anionic polymer includes aniionic amino acid polymer or poly-amino acid (such as poly-L-glutamic acid, poly-D-glutamic acid, poly-L-aspartic acid, poly-D-aspartic acid), poly-acrylic acid, polynucleotides, poly galacturonic acid, and poly vinyl sulfate.
Owner:INOVIO PHARMA

Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them

The present invention relates to novel microparticles formed of amphiphilic polyamino acids which transport active principle(s), AP(s), in particular protein and peptide active principle(s), and to novel modified-release pharmaceutical formulations comprising said AP microparticles. The aim of the invention is to develop novel microparticles, charged with AP, obtained by aggregation of nanoparticles of amphiphilic polyamino acids and having improved properties, in particular in the dry solid form, with regard to their ability to be dispersed and, concerning the reconstituted suspension, its stability and its ability to be easily handled and injected. The invention relates firstly to microparticles of amphiphilic polyamino acid (PO) comprising at least one AP (associated noncovalently) which spontaneously form a colloidal suspension of nanoparticles in water, at pH 7.0, under isotonic conditions; which microparticles a. are obtained by atomization of a solution or colloidal suspension of PO comprising at least one AP, b. have a size of between 0.5 and 100 microns, c. and are dispersible in colloidal suspension. The invention also relates to the process for the preparation of these microparticles, to a liquid formulation comprising a suspension of these PO / AP microparticles, to a reconstitution process and kit for this formulation and to a dry form of this formulation.
Owner:FLAMEL TECHNOLOGIES

Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation

In this invention, a release-delaying system is to be developed for LHRH antagonists, in particular for cetrorelix, which allows the active compound to be released in a controlled manner over several weeks by complexation with suitable biophilic carriers. The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with cetrorelix. The cetrorelix polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P2O5 in vacuo. If complexes having a defined composition are to be obtained, lyophilization proves to be a suitable method. The cetrorelix-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the cetrorelix-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of cetrorelix with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.
Owner:ZENTARIS GMBH

Hair cosmetic and styling compositions based on maleic acid copolymers and polyamines

Disclosed are cosmetic compositions which include hair cosmetic or styling compositions, comprising: a maleic acid copolymer; a polyamine selected from polyamino acids and aminated polysaccharides; a neutralizer; and water, wherein the polyamine is present in an amount less than 0.1% by weight based on the total weight of the composition, and methods of making and using the compositions to impart or maintain hair style.
Owner:LOREAL SA

Non-phosphorus reverse osmosis membrane scale inhibitor and preparation method thereof

The invention discloses a non-phosphorus reverse osmosis membrane scale inhibitor and a preparation method thereof. The non-phosphorus reverse osmosis membrane scale inhibitor comprises the following components: 5-20% of carboxylic acid polymer, 6-36% of sulfonic acid copolymer, 5-15% of polyamino acid, 0.1-20% of Dimethyldioctadecylammonium bromide and the balance deionized water. The preparation method is as follows: adding the above components in a container at room temperature, and stirring to form a uniform and transparent solution. The non-phosphorus reverse osmosis membrane scale inhibitor provided by the invention is suitable for pretreatment of surface water, can efficiently prevent inorganic scales and colloid scales from depositing on a reverse osmosis membrane, ensures the pH value to be 2-7 in the use process, has no toxicity and good compatibility with a common flocculant, can not cause any damage on the membrane compared with acid.
Owner:北京蓝星清洗有限公司

Topical cosmetic formulations for regulating and improving the moisture content of the skin

Cosmetic and / or dermatological formulations for the topical treatment of the skin for regulating and improving the moisture content of the skin, comprising as active ingredient combination a) at least one anionic polyamino acid matrix, b) at least one polysaccharide, and optionally c) one or more osmoprotectants for topical application are provided.
Owner:EVONIK GOLDSCHMIDT GMBH

Spherical amino acid adsorbent and its preparation method

The present invention relates to a ring amino acid adsorbing agent and its preparation method. It uses natural macromolecule as carrier, its grain size is 0.45-0.9 mm, it is formed from resin which has amino acid ligand with fixed effective dose after activation of epoxy chloropropane, in which amino acid content is 12.5-39.7 micro mol / ml resin, and the described ligand is: amino acid, polyamino acid, polypeptide or protein. It can be directly used for blood perfusion method to cure the diseases of rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, endotoxemia and infective shock, etc. The animal tests show that adsorbing agent has no toxic side effect and heat source. It is a good medical blood-cleaning adsorption material.
Owner:JAFRON BIOMEDICAL

Dispersion of polyamino acids in a continuous lipid phase

The invention relates to injectable pharmaceutical compositions for the prolonged release of at least one active principle, comprising at least one active principle in an aqueous phase of amphiphilic polymer, said aqueous phase being in the form of a dispersion in a continuous lipid phase. The composition is in the form of a water-in-oil emulsion comprising:a pharmaceutically acceptable, continuous lipid phase,an aqueous disperse phase containing at least one amphiphilic polymer and at least one active principle not covalently bonded to said amphiphilic polymer, andat least one pharmaceutically acceptable surfactant.
Owner:FLAMEL TECHNOLOGIES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products